• 1. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Professional Introduction to Compound with CAS No. 105391-76-2 and Product Name: 5-(Trifluoromethoxy)-1H-indazole

5-(Trifluoromethoxy)-1H-indazole, identified by the Chemical Abstracts Service Number (CAS No.) 105391-76-2, is a fluorinated heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the indazole class, a structural motif widely recognized for its biological activity and potential therapeutic applications. The presence of a trifluoromethoxy substituent in its molecular structure imparts unique electronic and steric properties, making it a valuable scaffold for drug discovery and development.

The trifluoromethoxy group is particularly noteworthy due to its ability to modulate the pharmacokinetic and pharmacodynamic profiles of molecules. Fluoro substitution, especially in the form of trifluoromethoxy, has been extensively studied for its ability to enhance metabolic stability, improve lipophilicity, and increase binding affinity to biological targets. These attributes make 5-(Trifluoromethoxy)-1H-indazole a promising candidate for further exploration in medicinal chemistry.

In recent years, there has been a surge in research focused on indazole derivatives due to their diverse biological activities. Studies have demonstrated that indazole-based compounds exhibit properties relevant to various therapeutic areas, including anticancer, anti-inflammatory, and antimicrobial applications. The introduction of fluorine atoms into these structures often enhances their biological efficacy by improving interactions with enzymes and receptors.

One of the most compelling aspects of 5-(Trifluoromethoxy)-1H-indazole is its potential as a lead compound for the development of novel therapeutics. Researchers have leveraged computational modeling and high-throughput screening techniques to identify derivatives of this compound that may exhibit enhanced activity against specific disease targets. For instance, studies have suggested that modifications in the indazole core can lead to compounds with improved selectivity for certain enzymes or receptors involved in pathological processes.

The trifluoromethoxy group plays a critical role in fine-tuning the pharmacological properties of 5-(Trifluoromethoxy)-1H-indazole. This substituent influences both the electronic distribution within the molecule and its interaction with biological systems. The electron-withdrawing nature of fluorine atoms can increase the lipophilicity of the compound, facilitating better membrane penetration and cellular uptake. Additionally, the methoxy group contributes to hydrogen bonding capabilities, which can be crucial for binding to specific biological targets.

Recent advancements in synthetic chemistry have enabled the efficient preparation of complex indazole derivatives, including those featuring fluorinated moieties. Techniques such as palladium-catalyzed cross-coupling reactions and fluorination methods have been instrumental in constructing these molecules with high precision. These synthetic strategies allow chemists to explore a wide range of structural variations, thereby expanding the chemical space available for drug discovery.

The pharmacological evaluation of 5-(Trifluoromethoxy)-1H-indazole has revealed intriguing findings that warrant further investigation. Preclinical studies have indicated potential activity against various disease models, including those relevant to cancer and inflammatory disorders. The compound's ability to modulate key signaling pathways has been highlighted in several publications, suggesting its therapeutic promise.

In conclusion, 5-(Trifluoromethoxy)-1H-indazole (CAS No. 105391-76-2) represents a significant advancement in medicinal chemistry due to its unique structural features and biological potential. The combination of the indazole core with the trifluoromethoxy substituent creates a versatile scaffold for developing novel therapeutics. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in addressing unmet medical needs across multiple therapeutic areas.

• 1315359-33-1(6-(Difluoromethoxy)-1H-indazole)
• 2676196-05-5(1H-Indazole, 7-bromo-5-(trifluoromethoxy)-)
• 2244087-63-4(1H-Indazole, 7-(trifluoromethoxy)-)
• 3522-07-4(6-Methoxyindazole)
• 620989-10-8(1H-Indazole, 5-(4-methoxyphenoxy)-)
• 105391-65-9(5-(Difluoromethoxy)-1H-indazole)
• 105391-43-3(6-(Trifluoromethoxy)-1H-indazole)
• 94444-96-9(5-Methoxy-1H-indazole)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)